#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	12022	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2227	529.3	0	.	n	.	0	C1450T	SNP	1450	1450	C	1662	1662	T	664	T,C	621,20	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	12022	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2227	529.3	1	SNP	n	C1184T	0	.	.	1184	1184	C	1396	1396	C	655	C,T	623,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	22078	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3591	606.1	0	.	n	.	0	A1223G	SNP	1223	1223	A	1572	1572	G	708	G,A	680,8	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	22078	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3591	606.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2320	2320	C	635	C	616	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	22078	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3591	606.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2394	2394	A	639	A	612	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	22078	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3591	606.1	1	SNP	n	C2597T	0	.	.	2597	2597	C	2946	2946	C	654	C	633	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	22078	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3591	606.1	0	HET	.	.	.	G930A	.	930	930	G	1279	1279	G	750	G,A	548,166	.	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	1454	folP	855	855	100.0	folP.l15.c4.ctg.1	1573	90.5	1	SNP	p	R229S	1	.	.	685	687	AGC	1131	1133	AGC	140;140;139	A;G;C	138;137;132	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_Z_01155	gyrA.WHO_Z_01155	1	1	27	4616	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3406	133.4	1	SNP	p	S91F	1	.	.	271	273	TTC	628	630	TTC	169;169;169	T;T;C	161;160;159	gyrA.WHO_Z_01155:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_Z_01155	gyrA.WHO_Z_01155	1	1	27	4616	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3406	133.4	1	SNP	p	D95N	1	.	.	283	285	AAC	640	642	AAC	162;161;164	A,G;A,G;C,T	151,1;151,1;152,1	gyrA.WHO_Z_01155:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_Z_01155	gyrA.WHO_Z_01155	1	1	27	4616	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3406	133.4	1	SNP	p	N95G	0	.	.	283	285	AAC	640	642	AAC	162;161;164	A,G;A,G;C,T	151,1;151,1;152,1	gyrA.WHO_Z_01155:1:1:N95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1254	mtrR	633	633	99.37	mtrR.l15.c4.ctg.1	1399	88.5	0	.	p	.	0	A39T	NONSYN	115	117	GCC	465	467	ACC	130;129;129	A,G;C;C	123,1;127;127	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1254	mtrR	633	633	99.37	mtrR.l15.c4.ctg.1	1399	88.5	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	663	665	CAC	144;146;146	C;A;C	140;141;142	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1254	mtrR	633	633	99.37	mtrR.l15.c4.ctg.1	1399	88.5	1	SNP	p	G45D	0	.	.	133	135	GGC	483	485	GGC	128;126;125	G;G;C	125;123;124	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	760	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	905	82.5	0	.	n	.	0	A197.	DEL	197	197	A	518	518	A	174	A	173	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	539	4088	parC	2304	2304	99.83	parC.l6.c30.ctg.1	3150	128.2	1	SNP	p	S87I	1	S87I	NONSYN	259	261	AGT	707	709	ATT	173;173;173	A,C;T,G;T	165,1;166,1;169	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	539	4088	parC	2304	2304	99.83	parC.l6.c30.ctg.1	3150	128.2	0	.	p	.	0	T518_Q519insR	INS	1552	1552	A	2001	2001	C	159	C	149	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	539	4088	parC	2304	2304	99.83	parC.l6.c30.ctg.1	3150	128.2	1	SNP	p	D86N	0	.	.	256	258	GAC	704	706	GAC	172;170;173	G;A;C	167;162;168	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	539	4088	parC	2304	2304	99.83	parC.l6.c30.ctg.1	3150	128.2	1	SNP	p	S88P	0	.	.	262	264	TCC	710	712	TCC	174;174;176	T;C;C	166;168;172	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	3094	parE	1986	1986	99.9	parE.l15.c4.ctg.1	2653	114.6	0	.	p	.	0	T35I	NONSYN	103	105	ACA	479	481	ATA	151;153;153	A;T,C;A	148;147,2;149	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	3094	parE	1986	1986	99.9	parE.l15.c4.ctg.1	2653	114.6	0	.	p	.	0	D437N	NONSYN	1309	1311	GAT	1685	1687	AAT	138;140;139	A,G;A;T	128,5;131;134	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	3094	parE	1986	1986	99.9	parE.l15.c4.ctg.1	2653	114.6	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1604	1606	GGC	159;158;156	G;G;C	152;151;147	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.18.001	penA.18.001	1	1	27	3082	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2590	116.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1277	1279	GCA	174;176;184	G;C;A,C	169;167;177,1	penA.18.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.18.001	penA.18.001	1	1	27	3082	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2590	116.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1280	1282	ATC	186;184;181	A;T;C,G,A	179;174;175,1,1	penA.18.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.18.001	penA.18.001	1	1	27	3082	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2590	116.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1292	1294	GTG	174;175;173	G,A;T,C;G,C	172,1;170,1;168,1	penA.18.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.18.001	penA.18.001	1	1	27	3082	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2590	116.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1292	1294	GTG	174;175;173	G,A;T,C;G,C	172,1;170,1;168,1	penA.18.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.18.001	penA.18.001	1	1	27	3082	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2590	116.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1796	1798	ACC	145;144;145	A,C;C;C	135,1;139;138	penA.18.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.18.001	penA.18.001	1	1	27	3082	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2590	116.8	1	SNP	p	T502P	0	.	.	1504	1506	ACG	1850	1852	ACG	143;142;140	A,G;C;G	117,1;121;119	penA.18.001:1:1:T502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.18.001	penA.18.001	1	1	27	3082	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2590	116.8	1	SNP	p	T502V	0	.	.	1504	1506	ACG	1850	1852	ACG	143;142;140	A,G;C;G	117,1;121;119	penA.18.001:1:1:T502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.18.001	penA.18.001	1	1	27	3082	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2590	116.8	1	SNP	p	G543S	1	.	.	1627	1629	AGC	1973	1975	AGC	118;116;114	A,G;G;C,T	104,2;107;102,2	penA.18.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.18.001	penA.18.001	1	1	27	3082	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2590	116.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1982	1984	GGC	104;102;101	G,A;G;C	95,3;97;95	penA.18.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.18.001	penA.18.001	1	1	27	3082	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2590	116.8	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2000	2002	CCG	92;98;99	C,CGG;C,G;G	76,1;87,1;84	penA.18.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	4760	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3037	154.7	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1581	1583	CCG	177;175;179	C;C,T,G;G	164;166,1,1;173	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1862	porA	1146	1146	99.74	porA.l6.c17.ctg.1	1841	99.4	0	.	p	.	0	S22G	NONSYN	64	66	AGC	385	387	GGC	125;124;127	G,A;G;C	118,2;117;122	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1862	porA	1146	1146	99.74	porA.l6.c17.ctg.1	1841	99.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	567	567	C	86	C,G	78,1	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	2400	porB1b	1041	1041	98.46	porB1b.l6.c4.ctg.1	1598	148.0	0	.	p	.	0	G46A	NONSYN	136	138	GGC	474	476	GCC	181;178;177	G,A;C,G,A;C,A	174,2;169,4,2;173,2	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	2400	porB1b	1041	1041	98.46	porB1b.l6.c4.ctg.1	1598	148.0	0	.	p	.	0	Q143K	NONSYN	427	429	CAA	765	767	AAA	172;174;174	A,C,G;A;A	162,4,1;169;166	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	2400	porB1b	1041	1041	98.46	porB1b.l6.c4.ctg.1	1598	148.0	0	.	p	.	0	A151V	NONSYN	451	453	GCA	789	791	GTA	174;171;171	G;T;A	171;164;162	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	2400	porB1b	1041	1041	98.46	porB1b.l6.c4.ctg.1	1598	148.0	0	.	p	.	0	S218G	NONSYN	652	654	AGT	990	992	GGT	192;195;190	G,A;G;T	182,1;190;183	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	2400	porB1b	1041	1041	98.46	porB1b.l6.c4.ctg.1	1598	148.0	0	.	p	.	0	T254A	NONSYN	760	762	ACA	1098	1100	GCA	181;178;179	G,A;C;A	177,1;175;176	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	2400	porB1b	1041	1041	98.46	porB1b.l6.c4.ctg.1	1598	148.0	0	.	p	.	0	Y255W	NONSYN	763	765	TAC	1101	1103	TGG	179;178;178	T,A;G,T;G	174,3;173,3;176	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	2400	porB1b	1041	1041	98.46	porB1b.l6.c4.ctg.1	1598	148.0	0	.	p	.	0	R256K	NONSYN	766	768	CGT	1104	1106	AAG	179;180;181	A,C;A,G;G,C,T	175,1;174,4;174,3,1	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	2400	porB1b	1041	1041	98.46	porB1b.l6.c4.ctg.1	1598	148.0	1	SNP	p	G120K	1	.	.	358	360	AAG	696	698	AAG	189;187;191	A;A;G	185;184;187	porB1b.WHO_X_02194c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	2400	porB1b	1041	1041	98.46	porB1b.l6.c4.ctg.1	1598	148.0	1	SNP	p	A121D	1	.	.	361	363	GAC	699	701	GAC	189;189;192	G,A;A,C;C	182,3;183,1;189	porB1b.WHO_X_02194c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	2400	porB1b	1041	1041	98.46	porB1b.l6.c4.ctg.1	1598	148.0	1	SNP	p	D121N	0	.	.	361	363	GAC	699	701	GAC	189;189;192	G,A;A,C;C	182,3;183,1;189	porB1b.WHO_X_02194c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	8246	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4759	170.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	894	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1203	73.6	1	SNP	p	V57M	1	.	.	169	171	ATG	583	585	ATG	170;170;170	A;T;G	166;166;164	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
